
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· July 28, 2026 · 23 min read
By Ran Chen#FDA Approval#Wet AMD#Anti-VEGF

Pricing & Access· July 27, 2026 · 18 min read
Multiple Sclerosis Disease-Modifying Therapy Access Landscape (2026)
By Ran Chen#Multiple Sclerosis#Biosimilars#Patent Cliff

Approvals· July 27, 2026 · 18 min read
Sickle Cell Disease Treatment Access Landscape: Casgevy, Lyfgenia & Oxbryta

Pipeline· July 26, 2026 · 18 min read
Alzheimer's Disease Clinical Trials by the Numbers: 2026 Registry Analysis

Policy· July 26, 2026 · 18 min read
AMR Pipeline by the Numbers: FDA Antibacterials and the PASTEUR Act

Policy· July 25, 2026 · 28 min read
FDA Boxed Warnings by the Numbers (2026): 1,084 Ingredients, NSAIDs Lead
By Ran Chen#Label Warnings#Boxed Warning#FDA Approval

Generics· July 25, 2026 · 21 min read
FDA Green Book by the Numbers (2026): 2,882 Approved Animal Drugs, Zoetis Leads
By Ran Chen#FDA Approval#Generics#NADA

Manufacturing· July 24, 2026 · 17 min read
FDA AI/ML-Enabled Medical Devices by the Numbers (2026): 1,451 Cleared and Counting

Global· July 24, 2026 · 17 min read
EU vs US Biosimilars by the Numbers (2026): An EMA and FDA Purple Book Registry Comparison
By Ran Chen#Biosimilars#EMA#FDA Approval

Manufacturing· July 20, 2026 · 20 min read